7ca9c52f-2d6e-4868-b4e8-9dd7937f6b2b
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.600
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.600
- IL6_JAK_STAT3_SIGNALING+0.500
- COMPLEMENT+0.400
- INFLAMMATORY_RESPONSE+0.400
- KRAS_SIGNALING_UP+0.400
- ANGIOGENESIS+0.200
- APICAL_SURFACE+0.200
- APOPTOSIS+0.100
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- MYC_TARGETS_V1-0.500
- DNA_REPAIR-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- ESTROGEN_RESPONSE_EARLY-0.300
- GLYCOLYSIS-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- ADIPOGENESIS-0.200
- ESTROGEN_RESPONSE_LATE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-00433 | — | cohortMD2 | 0.867 |
| 2 | SRR12696760 | — | — | 0.850 |
| 3 | SRR818270 | GTEX | — | 0.849 |
| 4 | TCGA-55-6971-01A-11R-1949-07 | — | cohortMD2 | 0.849 |
| 5 | SRR1369219 | GTEX | — | 0.843 |
| 6 | 2d12ea90-c4f4-4aca-b353-360057b446e2 | — | — | 0.836 |
| 7 | SRR608598 | GTEX | — | 0.830 |
| 8 | TCGA-55-6979-01A-11R-1949-07 | — | cohortA1 | 0.828 |
| 9 | C3L-03976 | — | cohortMD2 | 0.827 |
| 10 | TCGA-CV-7410-01A-21R-2081-07 | — | — | 0.825 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |